Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -1.94M | -2.67M | -3.79M | -3.49M | -5.52M |
| Total Depreciation and Amortization | 980.10K | 1.00M | 1.16M | 1.04M | 1.10M |
| Total Amortization of Deferred Charges | 16.20K | 116.90K | 308.60K | 216.60K | -- |
| Total Other Non-Cash Items | 28.00K | 543.50K | 2.11M | 1.50K | -21.80K |
| Change in Net Operating Assets | 737.90K | 482.70K | -1.44M | -396.90K | 1.64M |
| Cash from Operations | -173.10K | -526.20K | -1.65M | -2.63M | -2.81M |
| Capital Expenditure | -220.20K | -101.90K | -341.10K | -181.80K | -525.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | -109.40K | 13.30K | 0.00 | -458.40K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.60K | 63.70K | 0.00 | 14.10K | 75.90K |
| Cash from Investing | -229.80K | -147.70K | -327.80K | -167.70K | -907.70K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -310.00K | -405.00K | -382.00K | -379.00K | -305.00K |
| Issuance of Common Stock | -- | -- | 1.00K | 97.00K | 499.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -228.30K | -303.60K | -281.30K | -209.20K | 145.80K |
| Foreign Exchange rate Adjustments | 109.00K | -186.70K | 11.80K | 234.40K | 432.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -522.10K | -1.16M | -2.25M | -2.77M | -3.14M |